文献速递免疫规划卫生政策与健康促进

韩国老年人中20价肺炎球菌结合疫苗与23价肺炎球菌多糖疫苗的成本效果比较

Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
PubMed 文献 · Vaccine · 2024-01-14

本研究在韩国65岁及以上人群中构建马尔可夫模型,比较PCV20与PPSV23的成本效果。结果显示,与PPSV23相比,PCV20可预防更多IPD和NBP病例及死亡,人均医疗费用高12.11美元,ICER为2677美元/QALY,低于16824美元/QALY的阈值,PCV20是具有成本效果的选项。

要点

  • 在韩国65岁及以上人群中,PCV20相比PPSV23可预防更多IPD和NBP病例及死亡。
  • PCV20人均医疗费用较PPSV23高12.11美元,人均获得0.0045个QALY。
  • PCV20的ICER为2677美元/QALY,低于16824美元/QALY的成本效果阈值。

核心结论

  • 在韩国65岁及以上成人中,与PPSV23相比,PCV20是具有成本效果的选项。

研究设计与样本

  • 构建马尔可夫模型,纳入易感状态、侵袭性肺炎球菌疾病(IPD)、非菌血症性肺炎(NBP)和死亡状态。
  • 人群按疾病风险状态(低风险、中风险、高风险)和入模年龄组(65-74岁/75-84岁/85-99岁)分类。
  • 总人群样本量为8,843,072人。

主要发现

  • 在总人群(n=8,843,072)中,与PPSV23相比,PCV20分别预防1941例IPD和50,575例NBP,以及898例IPD死亡和8593例NBP死亡。
  • PCV20的人均总医疗费用较PPSV23高12.11美元,人均获得0.0053个生命年和0.0045个质量调整生命年(QALY)。
  • PCV20与PPSV23的ICER分别为2270美元/生命年和2677美元/QALY。

关键数值与推荐

  • 成本效果阈值:16824美元/QALY。
  • PCV20的ICER为2677美元/QALY,低于阈值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the demonstrated immunogenicity and safety of the 20-valent pneumococcal conjugate vaccine (PCV20) in older adults, the cost-effectiveness of the PCV20 was not examined compared to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in South Korea. Therefore, this study aimed to evaluate the cost-effectiveness of PCV20 compared with PPSV23 in adults aged 65 years and older in South Korea. METHODS: We constructed a Markov model that included susceptible states, invasive pneumococcal disease (IPD), non-bacteremic pneumonia (NBP), and death. The population was categorized by disease risk status (low risk, moderate risk, and high risk) and age group (65-74/75-84/85-99 years) at model entry. The annual incidence and mortality of IPD and NBP associated with PCV20 and PPSV23 were estimated based on serotype coverage, vaccine coverage, and vaccine effectiveness. The disease costs and utilities were obtained from previous studies. The incremental cost-effectiveness ratio (ICER) was used to evaluate cost-effectiveness within the threshold of 16,824 USD per quality-adjusted life-year (QALY). RESULTS: Among the total population (n = 8,843,072), PCV20 prevented 1941 and 50,575 cases of IPDs and NBPs, respectively, and 898 and 8593 deaths due to IPDs and NBPs compared to PPSV23. The total medical cost per person was 12.11 USD higher in PCV20, with a gain of 0.0053 LYs and 0.0045 QALYs per person. The ICER for PCV20 and PPSV23 was 2270 USD/LY and 2677 USD/QALY. CONCLUSIONS: In South Korea, PCV20 is a cost-effective option compared with PPSV23 for adults aged 65 years and older. These cost-effectiveness results provide evidence for decision-making regarding the approval and National Immunization Program implementation of PCV20.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kang DW, Kim CR, Song JY, et al. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea. Vaccine. 2024. PMID: 38225184. doi:10.1016/j.vaccine.2024.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。